FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2322841476> ?p ?o ?g. }

• W2322841476 abstract "Purpose: Members of the fibroblast growth factor receptor family (FGFR1–4) are dysregulated in a number of cancer types and play key roles in tumorigenesis. In particular, activating mutations in FGFR2 have been identified in 16% of endometrial tumors. Such mutations have been shown to occur frequently alongside PTEN mutations, resulting in simultaneous activation of the MAPK and mTOR pathways. Here we evaluated the activity of the multi‐targeted kinase inhibitor AP24534, which is currently in phase 1 clinical testing, against FGFR2 and other FGFR family members, and investigated the ability of AP24534, plus the mTOR inhibitor ridaforolimus, to inhibit growth in endometrial cancer models. Results: We first evaluated the ability of AP24534 to block FGFR signaling and inhibit growth of FGFR‐driven cell lines. AP24534 potently blocked signaling of all 4 FGFRs with IC50s between 4–65 nM. This correlated with anti‐proliferative activity observed across a panel of cell lines, with GI50s between 10–275 nM. The anti‐proliferative activity of AP24534 compared favorably to that of other agents reported to have anti‐FGFR activity (i.e. AZD2171, CHIR‐258, BIBF 1120 and BMS‐540215). In endometrial cancer models AP24534 potently inhibited growth of 2 lines with an activating FGFR2 mutation (N549K), that differ in PTEN status, AN3CA (PTEN−/−) and MFE‐296 (PTEN+/+), with GI50s of 30 and 90 nM, respectively. AP24534 was less potent in 2 FGFR wild type lines, HEC‐1B and RL95.2, with GI50s of approximately 500 nM. To determine whether the anti‐proliferative activity of AP24534 could be enhanced by an mTOR inhibitor, we treated cells with the combination of ridaforolimus and AP24534. The combination synergistically inhibited proliferation of both AN3CA and MFE‐296 cells with combination index values of Conclusion: AP24534 is a pan‐FGFR inhibitor with potent activity in a variety of FGFR‐driven tumor models. Dual inhibition of FGFR2 by AP24534 and mTOR by ridaforolimus leads to synergistic activity in FGFR2‐driven endometrial cancer models in vitro, and tumor regression in the AN3CA xenograft model. These data provide support for the clinical testing of AP24534 in combination with ridaforolimus to treat FGFR2‐driven endometrial cancers. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B259." @default.
• W2322841476 created "2016-06-24" @default.
• W2322841476 creator A5000075307 @default.
• W2322841476 creator A5003638809 @default.
• W2322841476 creator A5007400441 @default.
• W2322841476 creator A5028196907 @default.
• W2322841476 creator A5030594054 @default.
• W2322841476 creator A5030692726 @default.
• W2322841476 creator A5035320303 @default.
• W2322841476 creator A5047497236 @default.
• W2322841476 creator A5060754365 @default.
• W2322841476 creator A5070011534 @default.
• W2322841476 creator A5077797768 @default.
• W2322841476 creator A5077826929 @default.
• W2322841476 creator A5079641841 @default.
• W2322841476 date "2009-12-10" @default.
• W2322841476 modified "2023-09-22" @default.
• W2322841476 title "Abstract B259: Combined targeting of FGFR2 and mTOR by AP24534 and ridaforolimus results in synergistic antitumor activity in FGFR2‐driven endometrial cancer models" @default.
• W2322841476 doi "https://doi.org/10.1158/1535-7163.targ-09-b259" @default.
• W2322841476 hasPublicationYear "2009" @default.
• W2322841476 type Work @default.
• W2322841476 sameAs 2322841476 @default.
• W2322841476 citedByCount "0" @default.
• W2322841476 crossrefType "proceedings-article" @default.
• W2322841476 hasAuthorship W2322841476A5000075307 @default.
• W2322841476 hasAuthorship W2322841476A5003638809 @default.
• W2322841476 hasAuthorship W2322841476A5007400441 @default.
• W2322841476 hasAuthorship W2322841476A5028196907 @default.
• W2322841476 hasAuthorship W2322841476A5030594054 @default.
• W2322841476 hasAuthorship W2322841476A5030692726 @default.
• W2322841476 hasAuthorship W2322841476A5035320303 @default.
• W2322841476 hasAuthorship W2322841476A5047497236 @default.
• W2322841476 hasAuthorship W2322841476A5060754365 @default.
• W2322841476 hasAuthorship W2322841476A5070011534 @default.
• W2322841476 hasAuthorship W2322841476A5077797768 @default.
• W2322841476 hasAuthorship W2322841476A5077826929 @default.
• W2322841476 hasAuthorship W2322841476A5079641841 @default.
• W2322841476 hasConcept C121608353 @default.
• W2322841476 hasConcept C126322002 @default.
• W2322841476 hasConcept C170493617 @default.
• W2322841476 hasConcept C184235292 @default.
• W2322841476 hasConcept C2777088508 @default.
• W2322841476 hasConcept C2777609662 @default.
• W2322841476 hasConcept C2779707156 @default.
• W2322841476 hasConcept C49418065 @default.
• W2322841476 hasConcept C502942594 @default.
• W2322841476 hasConcept C55493867 @default.
• W2322841476 hasConcept C555283112 @default.
• W2322841476 hasConcept C57074206 @default.
• W2322841476 hasConcept C62112901 @default.
• W2322841476 hasConcept C62478195 @default.
• W2322841476 hasConcept C71924100 @default.
• W2322841476 hasConcept C74373430 @default.
• W2322841476 hasConcept C82867764 @default.
• W2322841476 hasConcept C86554907 @default.
• W2322841476 hasConcept C86803240 @default.
• W2322841476 hasConcept C95444343 @default.
• W2322841476 hasConcept C98274493 @default.
• W2322841476 hasConceptScore W2322841476C121608353 @default.
• W2322841476 hasConceptScore W2322841476C126322002 @default.
• W2322841476 hasConceptScore W2322841476C170493617 @default.
• W2322841476 hasConceptScore W2322841476C184235292 @default.
• W2322841476 hasConceptScore W2322841476C2777088508 @default.
• W2322841476 hasConceptScore W2322841476C2777609662 @default.
• W2322841476 hasConceptScore W2322841476C2779707156 @default.
• W2322841476 hasConceptScore W2322841476C49418065 @default.
• W2322841476 hasConceptScore W2322841476C502942594 @default.
• W2322841476 hasConceptScore W2322841476C55493867 @default.
• W2322841476 hasConceptScore W2322841476C555283112 @default.
• W2322841476 hasConceptScore W2322841476C57074206 @default.
• W2322841476 hasConceptScore W2322841476C62112901 @default.
• W2322841476 hasConceptScore W2322841476C62478195 @default.
• W2322841476 hasConceptScore W2322841476C71924100 @default.
• W2322841476 hasConceptScore W2322841476C74373430 @default.
• W2322841476 hasConceptScore W2322841476C82867764 @default.
• W2322841476 hasConceptScore W2322841476C86554907 @default.
• W2322841476 hasConceptScore W2322841476C86803240 @default.
• W2322841476 hasConceptScore W2322841476C95444343 @default.
• W2322841476 hasConceptScore W2322841476C98274493 @default.
• W2322841476 hasLocation W23228414761 @default.
• W2322841476 hasOpenAccess W2322841476 @default.
• W2322841476 hasPrimaryLocation W23228414761 @default.
• W2322841476 hasRelatedWork W1519951345 @default.
• W2322841476 hasRelatedWork W1749374281 @default.
• W2322841476 hasRelatedWork W1973565962 @default.
• W2322841476 hasRelatedWork W1973723861 @default.
• W2322841476 hasRelatedWork W2032277190 @default.
• W2322841476 hasRelatedWork W2060275594 @default.
• W2322841476 hasRelatedWork W2078965581 @default.
• W2322841476 hasRelatedWork W2154213593 @default.
• W2322841476 hasRelatedWork W2254742212 @default.
• W2322841476 hasRelatedWork W2388597698 @default.
• W2322841476 hasRelatedWork W2480563537 @default.
• W2322841476 hasRelatedWork W2581181313 @default.
• W2322841476 hasRelatedWork W2581395526 @default.
• W2322841476 hasRelatedWork W2589716688 @default.
• W2322841476 hasRelatedWork W2885482630 @default.
• W2322841476 hasRelatedWork W2904745157 @default.
• W2322841476 hasRelatedWork W2997598382 @default.
• W2322841476 hasRelatedWork W3083321144 @default.

• next